The Big North-American Market Dinos (BMD)

Moderate and Mellow Market Methods

Sector Spotlight

Earlier this week, biopharmaceutical company Amgen Inc. Shelled out the big bucks, purchasing Horizon Therapeutics PLC for a whopping US $27 billion, making it this year’s largest healthcare acquisition. Amgen will pay $116.50 a share in cash, the companies said in a statement Monday, for a premium of about 48% since Horizon Therapeutics disclosed on Nov. 29 that it was in early talks with three suitors. Horizon shares gained as much as 15% on the news, while Amgen slipped by 1.5%.

​

As pharmaceutical companies move past the overwhelming focus on Covid-19, they are resuming their search for innovative therapies, especially for those that treat rare diseases and cancer. In the business of drug development, M&A deals are just as important as scientific breakthroughs. Over the last few years pharmaceutical M&A deals hit a record high as established pharmaceutical companies turned to new biotechs for innovation.

​

The deal for Horizon is the biggest in pharma since AstraZeneca Plc bought Alexion Pharmaceuticals for $39 billion in 2020. Horizon is developing drugs for conditions including lupus, alopecia, arthritis, and kidney transplant rejection. Meanwhile, Amgen is contending with the threat of diminished revenue as some of its most significant products will lose patent protection in the coming years.

​

​
​

Meme Stock Stalkers

Pump-and-Dumpers

It’s all fun and games until someone commits securities fraud. The Department of Justice (DOJ) and the Securities Exchange Commission (SEC) recently charged seven social media influencers with using Twitter and Discord (not Reddit, surprisingly enough) to commit securities fraud that netted them more than US $100 million in illegal profits.

​
​

Authorities alleged the defendants used the social media platforms to “pump” exchange-traded stocks in a scheme dating back to January 2020. Through widely followed Twitter accounts and stock trading chat rooms on Discord, these defendants allegedly “promoted themselves as successful traders,” according to an SEC press release, and encouraged followers to buy stocks they also purchased. What they didn’t do while promoting these stocks was disclose their plans to sell once share prices rose.

​
​

Doing research when you invest may not seem as glamorous as getting in on the hype of a meme stock, but it’s essential to ask yourself, “what’s in it for them?” when you see someone hyping up a stock online.

​
​
​

ESG

Driving Change

​
​

Chrysler, Dodge, Jeep, and Citroen parent company Stellantis announced an agreement with Detroit-based energy provider DTE Energy to add 400 megawatts of new solar projects in Michigan, enabling the automotive manufacturer to make massive progress towards its sustainability goals. The deal marks the second largest-ever renewable energy purchase from a U.S. utility and significantly adds to the solar installations in the state of Michigan.

​
​

Under the new agreement, Stellantis will buy clean energy through DTE’s voluntary renewable energy program, MIGreenPower. Stellantis said that by participating in the MIGreenPower program, it will be able to attribute 100% of its electricity use at 70 southeast Michigan sites to solar by 2026, reducing the company’s carbon emissions in North America by 50% and across its manufacturing facilities by 30%.

​
​
​
​
​

Financial Jargon Word of the Week: The terminal rate is the level at which a central bank is expected to stop raising interest rates. It’s the final stop on the rate hike schedule. ​ ​ In a sentence, please! It’s starting to look like the Bank of Canada’s terminal rate is going to be higher than expected. ​ ​ ​ ​ ​ ​ ​ Discover your Investor Profile and get customized free, action items specific to the way you invest! Every week, we will be talking about the latest market news and strategies, aligned to keep you sharp and armed for opportunity and volatility. This newsletter is geared to YOU, based on your own Finliti Investor Profile! We believe that every investor is unique and therefore, should be aware of their actual risk tolerance. If you’d like to know yours, please find out here: Finliti Investor Profile. Get actionable insights into your personalized faction once you discover your inner wealth warrior! Understanding your personal risk tolerance is one of the key first steps before embarking on an investment or trading strategy. It tells you your location on the GPS tracker to your financial destiny! Thank you for joining the Finliti Community! Finliti Disclaimer 1. Finliti’s newsletter is published as an information service to our subscribers and may contain references to stocks, bonds, mutual funds, ETFs, cryptoassets, etc., but this should not be construed as direct or indirect advice or recommendation to any reader to buy or sell these assets. 2. Finliti believes the sources it quotes to be reliable, but does not guarantee their accuracy or completeness. 3. Finliti is not paid by any company to recommend its stocks. 4. Employees or publishers of Finliti’s newsletter may own the assets discussed in the publication for their own investment purposes. 5. Past results are not necessarily indicative of future performance. 6. The information provided is for general information services to our readers as a convenience the materials are not a substitute for obtaining professional advice vis-a-vis your personal situation. 7. Given the time critical nature of the market, the information in this article may become outdated and Finliti has no obligation to change the article. 8. Finliti Corporation is not a registered Investment Advisor or Broker Dealer. This newsletter relies on the “publisher’s exclusion” from the definition of Investment Advisor under Section 202(a)(11)(D) of the Investment Advisors Act of 1940and its corresponding state securities laws and on the exemption from registration under Section 34 (1) (1) of the Securities Act (Ontario) and its equivalents in Canada. Tell your friends about us! Unsubscribe | Update your profile